Funder: Alzheimer's Association
Due Dates: March 26, 2026 (Letter of Intent) | April 30, 2026 (Full Application)
Funding Amounts: Up to $1,000,000 for Phase 1 projects; up to $2,000,000 for Phase 2–3 projects (rarely up to $3,000,000); project duration: 2–3 years.
Summary: Supports early-stage clinical trials of novel or repurposed drugs for Alzheimer’s disease and related dementias, advancing translational research and biomarker validation.
Key Information: LOI is required and must be submitted via ProposalCentral by 5:00 pm ET—late submissions will not be accepted.